Vertex, Genomics collaborate to use human genetics and machine learning to advance discovery of precision medicines
Vertex Pharmaceuticals Incorporated and Genomics plc announced a three-year collaboration, extendable to five years, to use human genetics and machine learning to improve discovery of targets for precision medicines, and to advance understanding of the clinical impact of human genetic variation and patient stratification in diseases with significant unmet need. The goal of the collaboration is to further advance Vertex’s efforts to develop transformative precision medicines for people with serious diseases. |